- Нетрадиційні методи лікування вазомоторних симптомів при згасанні репродуктивної та оваріальної функцій з позицій доказової медицини
Нетрадиційні методи лікування вазомоторних симптомів при згасанні репродуктивної та оваріальної функцій з позицій доказової медицини
HEALTH OF WOMAN. 2016.10(116):37–41
«Міжобласний центр медичної генетики і пренатальної діагностики», м. Кривий Ріг Національний медичний університет імені А. А. Богомольця, м. Київ Перинатальний центр, м. Київ
Проведено оцінювання різних методів лікування. Особливу увагу приділено менопаузальній гормональній терапії. Практичний лікар повинен бути поінформований про рівень доказів ефективності і безпеки нетрадиційних методів лікування, щоб запобігти недостатньому застосуванню ефективних і, навпаки, застосуванню неефективних або неприйнятних для пацієнток методів. Тому практичний лікар зобов’язаний у кожному конкретному випадку зробити індивідуальний вибір терапії, прийнятної для пацієнтки.
2. Rossouw J.E. Lessons learned from the Women’s Health Initiative trials of menopausal hormone therapy /J.E. Manson, A.M. Kaunitz, G.L. Anderson //Obstet. Gynecol. 2013; 121(1): 172–6. https://doi.org/10.1097/AOG.0b013e31827a08c8; PMid:23262943 PMCid:PMC3547645 3. Boekhout A.H. Management of hot flashes in patients who have breast cancer with venlafaxine and clonidine: a randomized, double-blind, placebo-controlled trial /A.D. Vincent, O.B. Dalesio, J. van den Bosch, J.H. Foekema-Tons, S. Adriaansz [et al.] //J. Clin. Oncol. 2011; 29(29): 3862–8. https://doi.org/10.1200/jco.2010.33.1298 4. Peng W. Critical review of complementary and alternative medicine use in menopause: focus on prevalence, motivation, decision-making, and communication /J. Adams, D.W. Sibbritt, J.E. Frawley //Menopause. 2014; 21(5): 536–48. https://doi.org/10.1097/GME.0b013e3182a46a3e; PMid:24104604 5. Gentry-Maharaj A. Use and perceived efficacy of complementary and alternative medicines after discontinuation of hormone therapy: a nested United Kingdom Collaborative Trial of Ovarian Cancer Screening cohort study /C. Karpinskyj, C. Glazer, M. Burnell, A. Ryan, L. Fraser [et al.]//Menopause. 2015; 22(4): 384–90. https://doi.org/10.1097/GME.0000000000000330; PMid:25290539 PMCid:PMC4470524 6. Schierbeck L.L. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomized trial /L. Rejnmark, C.L. Tofteng, L. Stilgren, P. Eiken, L. Mosekilde [et al.] //BMJ. 2012; 345: e6409. https://doi.org/10.1136/bmj.e6409; PMid:23048011 7. Lobo R.A. The hope for KEEPS //Climacteric. 2015; 18(2): 108–9. https://doi.org/10.3109/13697137.2015.1007428; PMid:25651981 8. Hodis H.N. Vascular effects of early versus late postmenopausal treatment with estradiol /W.J. Mack, V.W. Henderson, D. Shoupe, M.J. Budoff, L. Hwang-Levine [et al.] //N. Engl. J. Med. 2016; 374(13): 1221–31. https://doi.org/10.1056/NEJMoa1505241; PMid:27028912 PMCid:PMC4921205 9. Haney E.M. Effects of selective serotonin reuptake inhibitors on bone health in adults: time for recommendations about screening, prevention and management? /S.J. Warden, M.M. Bliziotes //Bone. 2010; 46(1): 13–7. https://doi.org/10.1016/j.bone.2009.07.083; PMid:19664737 PMCid:PMC3413453 10. Hayes L.P. Use of gabapentin for the management of natural or surgical menopausal hot flashes /D.G. Carroll, K.W. Kelley //Ann. Pharmacother. 2011; 45(3): 388–94. https://doi.org/10.1345/aph.1P366; PMid:21343402 11. Yureneva S.V. Alternative treatments of vasomotor symptoms in light of evidence-based medicine /L.M. Ilyinа, Z.H. Ebzeeva //Obstetrics and gynecology 2016; 6:32–38. 12. Toulis К.A. Gabapentin for the treatment of hot flashes in women with natural or tamoxifen-induced menopause: a systematic review and meta-analysis /T. Tzellos, D. Kouvelas, D.G. Goulis //Clin. Ther. 2009; 31(2): 221–35. 13. Smetnik V. «Non-operative gynecology» /L. Tumilovich //Moscow 2005:99. 14. Blumel J.E. Menopausal transition, physiopathology, clinical and treatment /M.N. Cruz, N.J. Aparicio //Medicina 2002; 62(l): 57–65. 15. Avis N.E. The Study of Women’s Health Across the Nation (SWAN). Duration of menopausal vasomotor symptoms over the menopause transition //S.L. Crawford, G. Greendale, J.T. Bromberger, S.A. Everson-Rose, E.B. Gold [et al.] //JAMA Intern. Med. 2015; 175(4): 531–9. 16. Zeleke B.M. Vasomotor and sexual symptoms in older Australian women: a cross-sectional study /R.J. Bell, B. Billah, S.R. Davis //Fertil. Steril. 2016; 105(1): 149–55. https://doi.org/10.1016/j.fertnstert.2015.09.017 17. Stuenkel C.A. Treatment of symptoms of the menopause: An Endocrine Society Clinical Practice Guideline /S.R. Davis, A. Gompel, M.A. Lumsden, M.H. Murad, J.V. Pinkerton, R.J. Santen //Clin. Endocrinol. Metab. 2015; 100(11): 3975–4011. 18. Smetnik V.P. Menopausal hormone therapy and health preservation of women of Mature age. Clinical recommendations (treatment protocols). – M.; 2015. 19. Baber R.J. The IMS Writing Group. 2016 IMS Recommendations on women’s midlife health and menopause hormone therapy /N. Panay, A. Fenton //Climacteric. 2016; 19(2): 109–50. https://doi.org/10.3109/13697137.2015.1129166; PMid:26872610 20. Maclennan A.H. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes /J.L. Broadbent, S. Lester, V. Moore //Cochrane Database Syst. Rev.2004; (4): CD002978. 21. Rossouw J.E. Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial /G.L. Anderson, R.L. Prentice, A.Z. LaCroix, C. Kooperberg, M.L. Stefanick [et al.] //JAMA. 2002; 288(3): 321–33. 22. Studd J. «PROFOX» – the post HRT nightmare //Climacteric. 2011; 14(2): 217–9. https://doi.org/10.3109/13697137.2010.529199; PMid:21105839 23. Mintziori G. EMAS position statement: non-hormonal management of menopausal vasomotor symptoms /I. Lambrinoudaki, D.G. Goulis, I. Ceausu, H. Depypere, C.T. Erel [et al.] //Maturitas. 2015; 81(3): 410–3. https://doi.org/10.1016/j.maturitas.2015.04.009; PMid:25982505 24. Nonhormonal management of menopause-associated vasomotor symptoms: 2015 position statement of The North American Menopause Society. Menopause. 2015; 22(11): 1155–74. 25. Daley A. Exercise for vasomotor menopausal symptoms /H. Stokes-Lampard, A. Thomas, C. MacArthur //Cochrane Database Syst. Rev. 2014; (11): CD006108. 26. Lethaby A. Phytoestrogens for menopausal vasomotor symptoms /J. Marjoribanks, F. Kronenberg, H. Roberts, J. Eden, J. Brown //Cochrane Database Syst. Rev. 2013; (12): CD001395. 27. Li L. Quantitative efficacy of soy isoflavones on menopausal hot flashes /Y. Lv, L. Xu, Q. Zheng //Br. J. Clin. Pharmacol. 2015; 79(4): 593–604. 28. Taku K. Extracted or synthesized soybean isoflavones reduce menopausal hot flash frequency and severity: systematic review and meta-analysis of randomized controlled trials /M.K. Melby, F. Kronenberg, M.S. Kurzer, M. Messina //Menopause. 2012; 19(7): 776–90. https://doi.org/10.1097/gme.0b013e3182410159; PMid:22433977 29. Schmidt M. Consensus: soy isoflavones as a first-line approach to the treatment of menopausal vasomotor complaints /K. Arjomand-Wolkart, M.H. Birkhauser, A.R. Genazzani, D.M. Gruber, J. Huber [et al.] //Gynecol. Endocrinol. 2016; 32(6): 427–30. https://doi.org/10.3109/09513590.2016.1152240 30. Setchell K.D. Equol: history, chemistry, and formation /C. Clerici //J. Nutr. 2010; 140(7): 1355S-62S. 31. EFSA Panel on Food Additives and Nutrient Sources Added to Food (ANS). Risk assessment for peri- and postmenopausal women taking food supplements containing isolated isoflavones //EFSA J. 2015; 13(10): 4246. 32. National Institute for Health and Clinical Excellence. NICE Clinical Guideline Menopause. 2015. Available at: https://www.nice.org.uk/guidance/ng23/resources/menopause-diagnosis-and- management-1837330217413. 33. Lipovac M. The effect of red clover isoflavone supplementation over vasomotor and menopausal symptoms in postmenopausal women /P. Chedraui, C. Gruenhut, A. Gocan, C. Kurz, B. Neuber, M. Imhof //Gynecol. Endocrinol. 2012; 28(3): 203–7. 34. Edena J.A. Phytoestrogens for menopausal symptoms: a review //Maturitas. 2012; 72(2): 157–9. https://doi.org/10.1016/j.maturitas.2012.03.006; PMid:22516278 35. Leach M.J. Black cohosh (Cimicifuga spp.) for menopausal symptoms /V. Moore //Cochrane Database Syst. Rev. 2012; (9): CD007244. PMid:22972105 36. Medicines and Healthcare products Regulatory Agency (MHRA). Liver failure case highlights need to use Black Cohosh remedies carefully //MHRA Press; 2012. Available at: press.office@mhra.psi.gov.uk 37. Fritz H. Black cohosh and breast cancer: a systematic review. Integr /D. Seely, J. McGowan, B. Skidmore, R. Fernandes, D.A. Kennedy [et al.] //Cancer Ther. 2014; 13(1): 12–29. https://doi.org/10.1177/1534735413477191 38. Shechter M. Oral magnesium supplementation inhibits platelet-dependent thrombosis in patients with coronary artery disease /C.N. Merz, M. Paul-Labrador, S.R. Meisel, R.K. Rude, M.D. Molloy [et al.] //Am. J. Cardiol. 1999; 84(2): 152–6. https://doi.org/10.1016/S0002-9149(99)00225-8 39. Van Laecke S. Thrombotic microangiopathy: a role for magnesium? /E.V. Nagler, R. Vanholder //Thromb. Haemost. 2012; 107(3): 399–408. https://doi.org/10.1160/TH11-08-0593; PMid:22274299 40. Nelson H.D. Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis /K.K. Vesco, E. Haney, R. Fu, A. Nedrow, J. Miller [et al.] //JAMA 2006; 295(17): 2057–71. https://doi.org/10.1001/jama.295.17.2057; PMid:16670414 41. Shams Т. SSRIs for hot flashes: a systematic review and meta-analysis of randomized trials /B. Firwana, F. Habib, A. Alshahrani, B. Alnouh, M.N. Murad, M.J. Ferwana //Gen. Intern. Med. 2014; 29(1): 204–13. https://doi.org/10.1007/s11606-013-2535-9 42. Rada G. Non- hormonal interventions for hot flushes in women with a history of breast cancer /D. Capurro, T. Pantoja, J. Corbalбn, G. Moreno, L.M. Letelier, C. Vera //Cochrane Database Syst. Rev. 2010; (9): CD004923. https://doi.org/10.1002/14651858.cd004923.pub2 43. Fisher W.I. Risk factors, pathophysiology, and treatment of hot flashes in cancer /A.K. Johnson, G.R. Elkins, J.L. Otte, D.S. Burns, M. Yu, J.S. Carpenter //CA Cancer J. Clin. 2013; 63(3): 167–92. https://doi.org/10.3322/caac.21171; PMid:23355109 PMCid:PMC3640615 44. Simon J.A. Low-dose paroxetine 7.5 mg for menopausal vasomotor symptoms: two randomized controlled trials /D.J. Portman, A.M. Kaunitz, H. Mekonnen, K. Kazempour, S. Bhaskar, J. Lippman //Menopause. 2013; 20(10): 1027–35. https://doi.org/10.1097/GME.0b013e3182a66aa7; PMid:24045678 45. Sun Z. Efficacy and safety of desvenlafaxine treatment for hot flashes associated with menopause: a meta-analysis of randomized controlled trials /Y. Hao, M. Zhang //Gynecol. Obstet. Invest. 2013; 75(4): 255–62. https://doi.org/10.1159/000348564 46. Joffe H. Low-dose estradiol and the serotonin-norepinephrine reuptake inhibitor venlafaxine for vasomotor symptoms: a randomized clinical trial /K.A. Guthrie, A.Z. LaCroix, S.D. Reed, K.E. Ensrud, J.E. Manson [et al.] //JAMA Intern. Med. 2014; 174(7): 1058–66. https://doi.org/10.1001/jamainternmed.2014.1891 47. Steams V. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine /M.D. Johnson, J.M. Rae, A. Morocho, A. Novielli, P. Bhargava [et al.] //J. Natl. Cancer Inst. 2003; 95(23): 1758–64. https://doi.org/10.1093/jnci/djg108 48. Веропотвелян П.Н. Клинический поход к метаболическому синдрому в менопаузальном периоде /A.A. Тамамшева, B.В. Радченко, Н.П. Веропотвелян, Н.В. Воленко //Медицинские аспекты здоровья женщины 2015; 2 (88): 48–57. 49. Gevorkyan M.A. Modern approach to the treatment of women with pathological menopause /I.B. Manukhin [et al.] //Medical Council. 2010; 3(4): 15–20. |